Company intelligence / Profile preview

AgenT Biotech

Ownership: Private
Development stage: Other

Overview

AgenT Biotech is developing a blood-based diagnostic test that uses machine learning and multiomics biomarkers to detect Alzheimer’s disease up to 20 years before symptoms appear. Their approach analyzes proteins and metabolites in blood plasma, aiming for high sensitivity and specificity by leveraging peripheral biomarkers rather than brain-derived markers. The technology is currently undergoing clinical validation with the goal of enabling routine early screening for Alzheimer’s

Therapeutic areas: Neurology
Modalities: Diagnostic test (Blood-based multiomics assay)Machine learning/AI-driven biomarker analysis
Industry: Protein Biomarker Diagnostics

Partnerships

INOVIE Group (clinical laboratory network partnership to advance clinical validation and deployment of the diagnostic test)

Beyond the preview

Go deeper on AgenT Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AgenT Biotech.

Explore the full profile